Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhoenix Group Holdings Regulatory News (PHNX)

  • There is currently no data for PHNX

Residency Update

30 Jan 2018 07:00

RNS Number : 2599D
Phoenix Group Holdings
30 January 2018
 

Phoenix Group Holdings

LEI: 21380031B1D56JRCE375

Notice to PGH shareholders and to holders of outstanding debt securities regarding change in the head office and tax residence of Phoenix Group Holdings ("PGH")

Further to the announcement dated 21 June 2017, notice is hereby given that with effect from 31 January 2018 the central management and control, and the head office, of PGH will move from Jersey to the United Kingdom, with the intention that PGH will be resident in the United Kingdom for tax purposes from such date.

With effect from 31 January 2018, the PRA will treat PGH, and not Phoenix Life Holdings Limited ("PLHL"), as the ultimate EEA insurance holding company of the Insurance Group.

Holders of the subordinated securities:

· £428,113,000 6.625 per cent. Guaranteed Subordinated Notes due 2025;

· £450,000,000 4.125 per cent. Tier 3 Notes due 2022 issued pursuant to PGH's £3,000,000,000 Euro Medium Term Note Programme; and

· U.S.$500,000,000 5.375 per cent. Notes due 2027 issued pursuant to PGH's £3,000,000,000 Euro Medium Term Note Programme,

each issued by PGH (together, the "Outstanding Subordinated Securities"), are hereby notified that as such, PGH will become the ultimate EEA insurance holding company and the Insurance Group Parent Entity and a member of the Insurance Group for the purposes of the terms and conditions of the Outstanding Subordinated Securities. This will result in the Outstanding Subordinated Securities (and not the relevant on-loan of the proceeds of the Outstanding Subordinated Securities) being the only relevant capital item for the purposes of the definition of "Capital Disqualification Event" under the Outstanding Subordinated Securities with effect from such date.

PLHL will no longer be required by the PRA to be taken into account for the purposes of the deferral of principal and interest on the Outstanding Subordinated Securities pursuant to the definitions of "Regulatory Deficiency Interest Deferral Event" and "Regulatory Deficiency Redemption Deferral Event".

Capitalised terms that are not defined in this announcement will have the meanings given to them in the terms and conditions of the Outstanding Subordinated Securities.

The change in tax residency is not expected to impact PGH shareholders, other than UK stamp duty reserve tax (currently levied at 0.5%) will be incurred on subsequent purchases of PGH depositary interests.

Any PGH shareholder who is uncertain of the implications of the change in PGH's tax residency on their investment is recommended to obtain professional advice.

The change in tax residency will not impact the terms and conditions of the £300,000,000 5.75 per cent. Bonds due 2021 (of which £121,610,000 remains outstanding).

For further information, please contact:

 

Debt investors:

Rashmin Shah, Group Treasurer, Phoenix Group

Telephone: +44 (0) 20 3735 0059

Email: rashmin.shah@thephoenixgroup.com

 

Equity investors/analysts:Sam Perowne, Head of Investor Relations, Phoenix GroupTelephone: +44 (0) 20 3735 0021

Email: Samuel.Perowne@thephoenixgroup.com

 

 

Website: www.thephoenixgroup.com

 

This notice does not constitute or form part of an offer to sell or the solicitation of an offer to subscribe for or otherwise acquire any securities.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRSEDFWUFASEDF
Date   Source Headline
10th Apr 20249:43 amRNSDirector/PDMR Shareholding
9th Apr 20248:33 amRNSDirector/PDMR Shareholding
8th Apr 20242:15 pmRNSNotice of AGM
3rd Apr 20241:02 pmRNSDirector/PDMR Shareholding
2nd Apr 20245:26 pmRNSTotal Voting Rights
2nd Apr 20244:45 pmRNSDirector/PDMR Shareholding
28th Mar 20245:40 pmRNSDirector/PDMR Shareholding
27th Mar 20244:20 pmRNSAnnual Financial Report
27th Mar 20242:45 pmRNSDirector/PDMR Shareholding
22nd Mar 20247:00 amRNS2023 Annual Financial Report
6th Mar 20242:00 pmRNSDirector/PDMR Shareholding
1st Mar 20249:35 amRNSTotal Voting Rights
6th Feb 20245:17 pmRNSDirector/PDMR Shareholding
2nd Feb 202410:56 amRNSTotal Voting Rights
1st Feb 20247:00 amRNS2023 Trading Statement
8th Jan 20245:09 pmRNSDirector/PDMR Shareholding
2nd Jan 20243:15 pmRNSTotal Voting Rights
11th Dec 20236:13 pmRNSBlock listing Interim Review
6th Dec 20234:28 pmRNSDirector/PDMR Shareholding
5th Dec 202311:42 amRNSFinal Result of Tender Offer
5th Dec 202310:22 amRNSIndicative Result of Tender Offer
5th Dec 20237:10 amRNSPublication of Final Terms
1st Dec 202311:46 amRNSTotal Voting Rights
28th Nov 20235:46 pmRNSIssue of Debt and Tender Maximum Acceptance Amount
27th Nov 20238:20 amRNSTender Offers and New Issue
24th Nov 202311:05 amRNSDirector Declaration
23rd Nov 20232:00 pmRNSPublication of Supplementary Prospectus
23rd Nov 202310:00 amRNSDirectorate Change
13th Nov 20237:00 amRNSUpgrade of near-term cash generation targets
7th Nov 20235:10 pmRNSDirector/PDMR Shareholding
1st Nov 20232:07 pmRNSDirector/PDMR Shareholding
31st Oct 20232:30 pmRNSHolding(s) in Company
25th Oct 20231:17 pmRNSDirector/PDMR Shareholding
25th Oct 20231:16 pmRNSDirector/PDMR Shareholding
9th Oct 202312:40 pmRNSDirector/PDMR Shareholding
9th Oct 202311:20 amRNSDirector/PDMR Shareholding
4th Oct 202310:00 amRNSBoard Changes
2nd Oct 20233:00 pmRNSPublication of Supplementary Prospectus
2nd Oct 20231:35 pmRNSTotal Voting Rights
29th Sep 20237:00 amRNSDirector/PDMR Shareholding
28th Sep 20232:46 pmRNSDirector/PDMR Shareholding
28th Sep 202312:49 pmRNSAvailability of Interim Financial Report
28th Sep 20237:00 amRNSInterim Financial Report
18th Sep 20237:00 amRNS2023 Interim Results
14th Sep 202310:00 amRNSHY23 reporting update
8th Sep 20239:33 amRNSDirector/PDMR Shareholding
1st Sep 20231:29 pmRNSTotal Voting Rights
9th Aug 20235:04 pmRNSDirector/PDMR Shareholding
1st Aug 20233:16 pmRNSTotal Voting Rights
7th Jul 20233:08 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.